Related Experiment Video
Updated: Apr 27, 2026
06:59
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
165
[Frequently associated genotypes to thrombophilia]
Helena Hernández-Cuervo1, Solangy Usme2, Juan J Yunis3
1Roskamp Laboratory, Department of Psychiatry and Neurosciences, University of South Florida, Tampa, Florida, USA.
Biomedica : Revista Del Instituto Nacional De Salud
|June 27, 2014
Summary
Venous thromboembolism (VTE) is a serious condition with genetic and environmental risk factors. This review details VTE formation, its complications, and key genetic causes like Factor V Leiden, particularly in Colombia.
Area of Science:
- Medical Science
- Pathology
- Genetics
Context:
- Venous thromboembolism (VTE) is a significant cause of morbidity worldwide.
- Incidence varies, affecting 1:100 adults and 1:100,000 children.
- VTE arises from genetic and environmental risk factors.
Purpose:
- To clarify the pathophysiology of thrombosis and thromboembolic disease.
- To identify the primary nosological entities associated with VTE.
- To highlight key genetic risk factors and their epidemiological significance.
Summary:
- This review explains thrombosis formation and its progression to thromboembolic disease.
- It details major VTE-related conditions and their genetic underpinnings.
- Focus is placed on epidemiologically significant genetic alterations, including Factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR C677T/A1298C.
- Specific attention is given to studies conducted in Colombia.
Impact:
- Provides a clear, concise overview of VTE for researchers and clinicians.
- Emphasizes the role of specific genetic mutations in VTE risk.
- Highlights regional epidemiological data from Colombia, aiding targeted public health strategies.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:30Venous Thrombosis I: Introduction
809
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
809
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119